Search
Filter Results
Displaying 321–330 of 732 for “Visions 2020”
-
May 2, 2022
Encouraging Clinical Trial Results for Alkeus’ Stargardt Disease Treatment
The company is also conducting a Phase 3 clinical trial of the emerging therapy for geographic atrophy.
-
The Karen And Basil Petrou Legacy Education Initiative
The Basil and Karen Petrou Education Initiative is born of the Foundation’s commitment to helping individuals ensure their estates do the best they can for their loved ones and the causes they care about. Debuting this year, the program will offer ongoing resources to help individuals and families explore and learn about end-of-life plans and strategies.
-
Jan 28, 2022
Kriya Therapeutics Licenses Emerging Foundation-Funded Dry AMD Gene Therapy
The Foundation Fighting Blindness is funding Bärb Rohrer, PhD, Medical University of South Carolina, to evaluate safety and efficacy of the gene therapy in a large animal model
-
Dec 13, 2021
Ocugen to Launch Clinical Trial for Cross-Cutting RP Gene Therapy
The clinical trial is for RHO and NR2E3 mutations, but the retinal gene therapy has the potential to benefit people with a variety of other mutated genes
-
May 14, 2021
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
More details from the clinical trial will be reported at a later date
-
Apr 29, 2021
Foundation Fighting Blindness and Usher 1F Collaborative to Launch Natural History Study
The project will help identify outcome measures for future clinical trials of potential USH1F therapies.
-
Mar 24, 2021
ProQR’s RNA Therapy for USH2A Performs Well in Phase 1/2 Clinical Trial
The company is planning two Phase 2/3 clinical trials for the treatment
-
Feb 4, 2021
Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision
Former Spark Therapeutics head of ophthalmic medical affairs, responsible for the development and approval of Luxturna™, to lead development of SparingVision’s proprietary asset, SPVN06, and further pipeline development
-
Nov 9, 2020
Stargazer Pharmaceuticals Initiates a Phase 2a Clinical Trial for its Stargardt Disease Drug
The Foundation Fighting Blindness Retinal Degeneration Fund is an investor in the company
-
Aug 4, 2020
4D Molecular Therapeutics Launches Phase 1 Clinical Trial for Choroideremia Gene Therapy
Gene therapy delivered by intravitreal injection